These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26602841)

  • 1. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Cancer Surgery: The New R-status Counts.
    Strobel O; Hank T; Hinz U; Bergmann F; Schneider L; Springfeld C; Jäger D; Schirmacher P; Hackert T; Büchler MW
    Ann Surg; 2017 Mar; 265(3):565-573. PubMed ID: 27918310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.
    Mitra A; Pai E; Dusane R; Ranganathan P; DeSouza A; Goel M; Shrikhande SV
    Langenbecks Arch Surg; 2018 Mar; 403(2):203-212. PubMed ID: 29362882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Well or poorly differentiated nonfunctioning neuroendocrine carcinoma of the pancreas: a single institution experience with 17 cases.
    Sellner F; Sobhian B; De Santis M; Pont J; Staettner S; Sellner S; Karner J; Klimpfinger M
    Eur J Surg Oncol; 2008 Feb; 34(2):191-5. PubMed ID: 17475440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
    Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
    J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
    Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
    World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
    Basturk O; Tang L; Hruban RH; Adsay V; Yang Z; Krasinskas AM; Vakiani E; La Rosa S; Jang KT; Frankel WL; Liu X; Zhang L; Giordano TJ; Bellizzi AM; Chen JH; Shi C; Allen P; Reidy DL; Wolfgang CL; Saka B; Rezaee N; Deshpande V; Klimstra DS
    Am J Surg Pathol; 2014 Apr; 38(4):437-47. PubMed ID: 24503751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
    Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
    Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.